Mark B. Juckett

Mark B. Juckett

Hematology | Hematology Oncology | Oncology
909 Fulton Street Southeast
Suite 214
Minneapolis, MN 55455

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 79 publications

Toward Standardized Screening for Chronic GVHD: Insights from the Engraft Learning Network.

Toward Standardized Screening for Chronic GVHD: Insights from the Engraft Learning Network.

Journal: Transplantation and cellular therapy
Published: June 26, 2026

Endpoints for clinical allograft trials; GRFS should not be abandoned.

Endpoints for clinical allograft trials; GRFS should not be abandoned.

Journal: Blood advances
Published: June 15, 2026

Clinical Predictors of Response in Chronic Graft-Versus-Host Disease: Results From the "Predicting the Quality of Response to Specific Treatments (PQRST)" Trial.

Clinical Predictors of Response in Chronic Graft-Versus-Host Disease: Results From the "Predicting the Quality of Response to Specific Treatments (PQRST)" Trial.

Journal: American journal of hematology
Published: May 18, 2026

Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

Journal: Blood
Published: March 18, 2026

Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial.

Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial.

Journal: Blood advances
Published: March 09, 2026

Donor-specific transplant outcomes from BMT CTN 1702: a multicenter prospective biologic assignment trial.

Donor-specific transplant outcomes from BMT CTN 1702: a multicenter prospective biologic assignment trial.

Journal: Blood advances
Published: March 09, 2026

Donor Search and Selection Strategy to Facilitate Comparable Transplant Rates across Donor Search Prognosis Groups: A Report from the BMT CTN 1702 Trial.

Donor Search and Selection Strategy to Facilitate Comparable Transplant Rates across Donor Search Prognosis Groups: A Report from the BMT CTN 1702 Trial.

Journal: Transplantation and cellular therapy
Published: December 04, 2025

A Behavioral Intervention to Improve Symptoms After Hematopoietic Cell Transplantation.

A Behavioral Intervention to Improve Symptoms After Hematopoietic Cell Transplantation.

Journal: Journal of pain and symptom management
Published: November 26, 2025

Impact of Publicly Reported Outcomes on Patient Selection for Hematopoietic Cell Transplantation.

Impact of Publicly Reported Outcomes on Patient Selection for Hematopoietic Cell Transplantation.

Journal: JCO oncology practice
Published: October 02, 2025

Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation.

Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 18, 2025

Longitudinal Study of Late Acute and Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: A Long-Term Follow-up Study from the Chronic Graft-Versus-Host Disease Consortium.

Longitudinal Study of Late Acute and Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: A Long-Term Follow-up Study from the Chronic Graft-Versus-Host Disease Consortium.

Journal: Transplantation and cellular therapy
Published: September 17, 2025

Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 Trial.

Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 Trial.

Journal: Transplantation and cellular therapy
Published: September 03, 2025
Showing 1-12 of 79

Last Updated: 09/26/2026